Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2025 19:37 ET | Source: Mangoceuticals, Inc.

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued...
November 13, 2025 07:00 ET | Source: Mangoceuticals, Inc.

Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health...
October 22, 2025 11:57 ET | Source: Spherix Global Insights

Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering

EXTON, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market...
September 30, 2025 11:16 ET | Source: The Law Offices of Frank R. Cruz

DEADLINE ALERT for NVO and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
September 29, 2025 10:14 ET | Source: Bragar Eagel & Squire

NOVO URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th

Novo allegedly overstated GLP-1 growth; stock plunged 21.8% on July 29, 2025 after lowering outlook due to compounded drugs, weak expansion, competition.
September 26, 2025 10:57 ET | Source: Bragar Eagel & Squire

NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th

Novo allegedly overstated GLP-1 growth potential; cut 2025 outlook citing compounded drugs and competition, causing shares to drop 21.8% in a day.
September 25, 2025 11:20 ET | Source: Faruqi & Faruqi LLP

Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or...
September 25, 2025 08:53 ET | Source: Berger Montague

DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025

PHILADELPHIA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”) on...
September 25, 2025 08:30 ET | Source: Bernstein Liebhard LLP

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

Novo Nordisk (NVO) Shareholder Lawsuit Filed - Contact Bernstein Liebhard For More Information
September 24, 2025 17:23 ET | Source: Bragar Eagel & Squire

NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th

The Novo lawsuit alleges it overstated GLP-1 growth potential; stock allegedly plunged 21.8% after cutting 2025 outlook on slower demand and competition.